Jingrong Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jingrong Cui has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Bo Xu
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
13 shared publicationsWei Guo
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking UniversityBeijing, China
8 shared publicationsMin Li
State Key Laboratory of Natural and Biomimetic Drugs , Peking University , Beijing 100191 , China
7 shared publicationsRuntao Li
Peking University
5 shared publicationsXia Yuan
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking UniversityBeijing, China
5 shared publications- Xiaomei Ling
Peking University
5 shared publications
Latest Publications
- Open Access
- 24 August 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 476
Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells
Proteasome inhibition interfering with many cell signaling pathways has been extensively explored as a therapeutic strategy for cancers. Proteasome inhibitor YSY01A is a novel agent that has shown remarkable anti-tumor effects; however, its mechanisms of action are not fully understood. Here we report that YSY01A is capable of suppressing cancer cell survival by induction of apoptosis. Paradoxically, we find that YSY01A abrogates constitutive activation of STAT3 via proteasome-independent degradation of gp130 and JAK2, but not transcriptional regulation, in human A549 non-small cell lung cancer cells. The reduction in gp130 and JAK2 can be restored by co-treatment with 3-methyladenine, an early-stage autophagy lysosome and type I/III PI3K inhibitor. YSY01A also effectively inhibits cancer cell migration and lung xenograft tumor growth with little adverse effect on animals. Thus, our findings suggest that YSY01A represents a promising candidate for further development of novel anticancer therapeutics targeting the proteasome.
- 24 August 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 476
Open AccessProteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells
Proteasome inhibition interfering with many cell signaling pathways has been extensively explored as a therapeutic strategy for cancers. Proteasome inhibitor YSY01A is a novel agent that has shown remarkable anti-tumor effects; however, its mechanisms of action are not fully understood. Here we report that YSY01A is capable of suppressing cancer cell survival by induction of apoptosis. Paradoxically, we find that YSY01A abrogates constitutive activation of STAT3 via proteasome-independent degradation of gp130 and JAK2, but not transcriptional regulation, in human A549 non-small cell lung cancer cells. The reduction in gp130 and JAK2 can be restored by co-treatment with 3-methyladenine, an early-stage autophagy lysosome and type I/III PI3K inhibitor. YSY01A also effectively inhibits cancer cell migration and lung xenograft tumor growth with little adverse effect on animals. Thus, our findings suggest that YSY01A represents a promising candidate for further development of novel anticancer therapeutics targeting the proteasome.
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (15) , 4031-4044
Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (15) , 4031-4044
Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors
- 1 January 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 125, 925-939
Urea-containing peptide boronic acids as potent proteasome inhibitors
- 1 January 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 125, 925-939
Urea-containing peptide boronic acids as potent proteasome inhibitors
- Open Access
- 1 January 2015
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 6 (8) , 701-708
Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo
YSY01A is a new tripeptideboronic acid and an analog of PS341. However, YSY01A's antitumor effects and mechanism have not yet been elucidated. This study demonstrates that YSY01A inhibited proteasome activity by combining with the chymotrypsin-like (CT-L) site (β5i/β5), the post-glutamyl peptide hydrolase (PGPH) site (β1i/β1) and the trypsin-like (T-L) site (β2i/β2) in special fluorgonic substrates and proteasome probe tests. We explored the anticancer effect using methyl thiazolyltetrazolium (MTT) or sulforhodamine B (SRB), and PC-3M cells were sensitive to YSY01A among the four cancer cell types tested. The YSY01A antiproliferative effect was stronger than that of PS341. In vivo, YSY01A (1.25, 2.25, and 3.25 mg/kg) inhibited PC-3M cell xenograft tumor growth, and the tumor volume inhibition rate was approximately 40% to 60%. YSY01A arrested PC-3M cells in the G2/M phase of the cell cycle by flow cytometry (FCM). Many proteins related to the cell cycle were analyzed using western blot, and YSY01A was shown to increase p21, p27, cyclinB1, P-cdc2 (tyr15) and wee1 protein expression in both cells and tumor tissue in a concentration-dependent manner. YSY01A, a proteasome inhibitor, exerts anticancer effects on PC-3M cells in vitro and in vivo. The mechanism of the YSY01A-mediated antitumor effect is that the cell cycle is arrested at the G2/M stage. This study suggests that YSY01A may be a novel therapeutic agent for prostate cancer.
- 1 January 2015
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 6 (8) , 701-708
Open AccessAnticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo
YSY01A is a new tripeptideboronic acid and an analog of PS341. However, YSY01A's antitumor effects and mechanism have not yet been elucidated. This study demonstrates that YSY01A inhibited proteasome activity by combining with the chymotrypsin-like (CT-L) site (β5i/β5), the post-glutamyl peptide hydrolase (PGPH) site (β1i/β1) and the trypsin-like (T-L) site (β2i/β2) in special fluorgonic substrates and proteasome probe tests. We explored the anticancer effect using methyl thiazolyltetrazolium (MTT) or sulforhodamine B (SRB), and PC-3M cells were sensitive to YSY01A among the four cancer cell types tested. The YSY01A antiproliferative effect was stronger than that of PS341. In vivo, YSY01A (1.25, 2.25, and 3.25 mg/kg) inhibited PC-3M cell xenograft tumor growth, and the tumor volume inhibition rate was approximately 40% to 60%. YSY01A arrested PC-3M cells in the G2/M phase of the cell cycle by flow cytometry (FCM). Many proteins related to the cell cycle were analyzed using western blot, and YSY01A was shown to increase p21, p27, cyclinB1, P-cdc2 (tyr15) and wee1 protein expression in both cells and tumor tissue in a concentration-dependent manner. YSY01A, a proteasome inhibitor, exerts anticancer effects on PC-3M cells in vitro and in vivo. The mechanism of the YSY01A-mediated antitumor effect is that the cell cycle is arrested at the G2/M stage. This study suggests that YSY01A may be a novel therapeutic agent for prostate cancer.
- Open Access
- 21 September 2014
- Published by Journal of Chinese Pharmaceutical Sciences in Journal of Chinese Pharmaceutical Sciences
- Vol. 23 (9)
Effects of compound YSY-01A, a novel proteasome inhibitor, on MGC-803 cells and its related mechanism
- 21 September 2014
- Published by Journal of Chinese Pharmaceutical Sciences in Journal of Chinese Pharmaceutical Sciences
- Vol. 23 (9)
Open AccessEffects of compound YSY-01A, a novel proteasome inhibitor, on MGC-803 cells and its related mechanism
- Open Access
- 20 August 2014
- Published by Journal of Chinese Pharmaceutical Sciences in Journal of Chinese Pharmaceutical Sciences
- Vol. 23 (8)
A new proteasome inhibitor YSY-01A induced autophagy in PC-3M cells
- 20 August 2014
- Published by Journal of Chinese Pharmaceutical Sciences in Journal of Chinese Pharmaceutical Sciences
- Vol. 23 (8)
Open AccessA new proteasome inhibitor YSY-01A induced autophagy in PC-3M cells
- 1 January 2013
- Published by China Science Publishing & Media Ltd. in Acta Agronomica Sinica
- Vol. 40 (8) , 748-72
Inhibition Effect and Mechanism of YSY-01A,a Novel Proteasome Inhibitor,on Tumor-induced Angiogenesis
Compound YSY-01A is a recently synthesized proteasome inhibitor.It has been proved for potent growth-inhibitory effect on tumor cells in previous studies.However,the effect of YSY-01A on tumor angiogenesis remains unclear.Our research aims to reveal the inhibition effect and mechanism of YSY-01A on tumor-induced angiogenesis.Firstly,we combined the Sulforhodamine B(SRB) assay and Transwell co-culture model to observe the inhibition of YSY-01A on human umbilical vein endothelial cells(HUVECs) proliferation induced by tumor cells(HT-29 cells).In succession,high content screening(HCS) assay was used to investigate effect of YSY-01A on NF-κB nuclear translocation in HT-29 cells.Finally,Western blot was used to measure the expression of hypoxia-inducible factor-1α(HIF-1α) and vascular endothelial growth factor(VEGF) in HT-29 cells inhibited by YSY-01A.To further determine mechanism of inhibition,SRB and HCS methods were used to investigate the effect of YSY-01A against HUVECs proliferation and motility,respectively.The results showed that YSY-01A could prohibit HUVECs proliferation induced by HT-29 cells in a concentration-dependent manner.Furthermore,YSY-01A significantly inhibited NF-κB nuclear translocation and reduced the expression of HIF-1α and VEGF in HT-29 cells.Further investigation revealed concentration-dependent suppress of YSY-01A on HUVECs proliferation and motility without obvious cytotoxic effect.In conclusion,through proteasome inhibition,YSY-01A could down-regulate pro-angiogenesis factors expression in tumor cells and exhibit remarkable anti-angiogenesis activity on vascular endothelial cells.
- 1 January 2013
- Published by China Science Publishing & Media Ltd. in Acta Agronomica Sinica
- Vol. 40 (8) , 748-72
Inhibition Effect and Mechanism of YSY-01A,a Novel Proteasome Inhibitor,on Tumor-induced Angiogenesis
Compound YSY-01A is a recently synthesized proteasome inhibitor.It has been proved for potent growth-inhibitory effect on tumor cells in previous studies.However,the effect of YSY-01A on tumor angiogenesis remains unclear.Our research aims to reveal the inhibition effect and mechanism of YSY-01A on tumor-induced angiogenesis.Firstly,we combined the Sulforhodamine B(SRB) assay and Transwell co-culture model to observe the inhibition of YSY-01A on human umbilical vein endothelial cells(HUVECs) proliferation induced by tumor cells(HT-29 cells).In succession,high content screening(HCS) assay was used to investigate effect of YSY-01A on NF-κB nuclear translocation in HT-29 cells.Finally,Western blot was used to measure the expression of hypoxia-inducible factor-1α(HIF-1α) and vascular endothelial growth factor(VEGF) in HT-29 cells inhibited by YSY-01A.To further determine mechanism of inhibition,SRB and HCS methods were used to investigate the effect of YSY-01A against HUVECs proliferation and motility,respectively.The results showed that YSY-01A could prohibit HUVECs proliferation induced by HT-29 cells in a concentration-dependent manner.Furthermore,YSY-01A significantly inhibited NF-κB nuclear translocation and reduced the expression of HIF-1α and VEGF in HT-29 cells.Further investigation revealed concentration-dependent suppress of YSY-01A on HUVECs proliferation and motility without obvious cytotoxic effect.In conclusion,through proteasome inhibition,YSY-01A could down-regulate pro-angiogenesis factors expression in tumor cells and exhibit remarkable anti-angiogenesis activity on vascular endothelial cells.
- Open Access
- 2 May 2012
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 44 (6) , 490-502
Angiogenesis inhibition and cell cycle arrest induced by treatment with Pseudolarix acid B alone or combined with 5-fluorouracil
Angiogenesis inhibitors combined with chemotherapeutic drugs have significant efficacy in the treatment of a variety of cancers. Pseudolarix acid B (PAB) is a traditional pregnancy-terminating agent, which has previously been shown to reduce tumor growth and angiogenesis. In this study, we used the high content screening assay to examine the effects of PAB on human umbilical vein endothelial cells (HUVECs). Two hepatocarcinoma 22-transplanted mouse models were used to determine PAB efficacy in combination with 5-fluorouracil (5-Fu). Our results suggested that PAB (0.156–1.250 μM) inhibited HUVECs motility in a concentration-dependent manner without obvious cytotoxicity in vitro. In vivo, PAB (25 mg/kg/day) promoted the anti-tumor efficacy of 5-Fu (5 mg/kg/2 days) in combination therapy, resulting in significantly higher tumor inhibition rates, lower microvessel density values, and prolonged survival times. It was also demonstrated that PAB acted by blocking the cell cycle at both the G1/S boundary and M phase, down-regulation of vascular endothelial growth factor, hypoxia-inducible factor 1α and cyclin E expression, and up-regulation of cdc2 expression. These observations provide the first evidence that PAB in combination with 5-Fu may be useful in cancer treatment.
- 2 May 2012
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 44 (6) , 490-502
Open AccessAngiogenesis inhibition and cell cycle arrest induced by treatment with Pseudolarix acid B alone or combined with 5-fluorouracil
Angiogenesis inhibitors combined with chemotherapeutic drugs have significant efficacy in the treatment of a variety of cancers. Pseudolarix acid B (PAB) is a traditional pregnancy-terminating agent, which has previously been shown to reduce tumor growth and angiogenesis. In this study, we used the high content screening assay to examine the effects of PAB on human umbilical vein endothelial cells (HUVECs). Two hepatocarcinoma 22-transplanted mouse models were used to determine PAB efficacy in combination with 5-fluorouracil (5-Fu). Our results suggested that PAB (0.156–1.250 μM) inhibited HUVECs motility in a concentration-dependent manner without obvious cytotoxicity in vitro. In vivo, PAB (25 mg/kg/day) promoted the anti-tumor efficacy of 5-Fu (5 mg/kg/2 days) in combination therapy, resulting in significantly higher tumor inhibition rates, lower microvessel density values, and prolonged survival times. It was also demonstrated that PAB acted by blocking the cell cycle at both the G1/S boundary and M phase, down-regulation of vascular endothelial growth factor, hypoxia-inducible factor 1α and cyclin E expression, and up-regulation of cdc2 expression. These observations provide the first evidence that PAB in combination with 5-Fu may be useful in cancer treatment.
- 8 February 2012
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (5) , 885-896
Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells
Pseudolaric acid B (PAB) is a diterpene acid isolated from the root and trunk bark of Pseudolaric kaempferi Gordon. Previous work has found that PAB has anti-inflammatory and anti-tumor effects in xenograft models of human hepatocellular carcinoma. The aim of this study is to evaluate the correlation between anti-cancer and anti-inflammatory effects of PAB and its molecular mechanisms on HT-29 cells. Production of prostaglandin E2 (PGE2) in HT-29 cells was evaluated by ELISA. mRNA of cyclooxygenase-2 (COX-2) was analyzed by RT-PCR assay. High-content screening (HCS) method was adopted to detect the cytokine mixture (CM)-induced transcription activity of NF-κB and STAT3. Western blotting was used to evaluate the protein expression levels of inflammatory mediators induced by CM. After treatment with PAB in various concentrations, the inhibition rate of cell proliferation was measured with sulforhodamine B assays. For the in vivo studies, tumor-bearing models xenografted with HT-29 cells were developed in nude mice, and following oral administration with PAB, tumor inhibition rate was calculated. PAB inhibited the PGE2 production in HT-29 cells significantly (P < 0.05) with similar results detected at the COX-2 mRNA level. Furthermore, PAB suppressed the COX-2 protein expression and significant nuclear translocation of NF-κB and STAT3 induced by CM, which correlated with a concomitant degradation of I-κB and a decrease in constitutive STAT3 phosphorylation (P < 0.05). Moreover, various concentrations of PAB inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. In vivo, after treatment with PAB for 17 days, the tumor weight of the 50 and 100 mg/kg treated groups was 0.62 ± 0.15 and 0.54 ± 0.06 g, respectively. When compared to the control group (0.82 ± 0.16 g), the inhibition rate of tumor weight was 24.2% at 50 mg/kg (P < 0.05) and 34.7% at 100 mg/kg (P < 0.001). PAB shows potential anti-cancer activity in HT-29 cells, and its molecular mechanisms are related to the anti-inflammatory action.
- 8 February 2012
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (5) , 885-896
Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells
Pseudolaric acid B (PAB) is a diterpene acid isolated from the root and trunk bark of Pseudolaric kaempferi Gordon. Previous work has found that PAB has anti-inflammatory and anti-tumor effects in xenograft models of human hepatocellular carcinoma. The aim of this study is to evaluate the correlation between anti-cancer and anti-inflammatory effects of PAB and its molecular mechanisms on HT-29 cells. Production of prostaglandin E2 (PGE2) in HT-29 cells was evaluated by ELISA. mRNA of cyclooxygenase-2 (COX-2) was analyzed by RT-PCR assay. High-content screening (HCS) method was adopted to detect the cytokine mixture (CM)-induced transcription activity of NF-κB and STAT3. Western blotting was used to evaluate the protein expression levels of inflammatory mediators induced by CM. After treatment with PAB in various concentrations, the inhibition rate of cell proliferation was measured with sulforhodamine B assays. For the in vivo studies, tumor-bearing models xenografted with HT-29 cells were developed in nude mice, and following oral administration with PAB, tumor inhibition rate was calculated. PAB inhibited the PGE2 production in HT-29 cells significantly (P < 0.05) with similar results detected at the COX-2 mRNA level. Furthermore, PAB suppressed the COX-2 protein expression and significant nuclear translocation of NF-κB and STAT3 induced by CM, which correlated with a concomitant degradation of I-κB and a decrease in constitutive STAT3 phosphorylation (P < 0.05). Moreover, various concentrations of PAB inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. In vivo, after treatment with PAB for 17 days, the tumor weight of the 50 and 100 mg/kg treated groups was 0.62 ± 0.15 and 0.54 ± 0.06 g, respectively. When compared to the control group (0.82 ± 0.16 g), the inhibition rate of tumor weight was 24.2% at 50 mg/kg (P < 0.05) and 34.7% at 100 mg/kg (P < 0.001). PAB shows potential anti-cancer activity in HT-29 cells, and its molecular mechanisms are related to the anti-inflammatory action.